Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actair (CEOLIA Pharma)
- Development stage
- Unknown
- Lead developer
- CEOLIA Pharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Actair (also known in Japan as Acitea) is a sublingual allergen immunotherapy tablet developed by Stallergenes Greer for the treatment of house dust mite-induced allergic rhinitis. The drug consists of a 50% mixture of allergen extracts from two prominent species of house dust mites: the European house dust mite (*Dermatophagoides pteronyssinus*) and the American house dust mite (*Dermatophagoides farinae*). Actair works by gradually exposing the patient's immune system to these allergens, which increases immunological tolerance, induces the production of allergen-specific IgG4 antibodies, and reduces allergic symptoms. Originally licensed to Shionogi in Japan, the marketing authorization and sales operations for Actair in Japan were transferred to CEOLIA Pharma in late 2026/early 2027.
- Brand names
- Acitea
- Other names
- AshiteaDermatophagoides farinae extract + Dermatophagoides pteronyssinus extracthouse dust mite allergen extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)sIgG4 (Allergen-specific immunoglobulin G4)CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on Actair (CEOLIA Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actair (CEOLIA Pharma).